Ekf Diagnostics Share Discussion Threads

[tongosti] 03/11/2021 11:54

Your language gives away who is who between us darling. Run out of arguments haven't we sweetheart? Read more and write less you Toby!

[mg1982] 03/11/2021 11:51

You really are thick - take it as a compliment.

As me and others have mentioned to you so many times - you are playing a different game (short term) to us (long term) ...that is fine, no problem but don't shove your opinions down our throat just like we don't

[tongosti] 03/11/2021 11:49

Stupidity is all on you son as that day marked the end (high of 82) of the then bull run. Now you're telling me that you bought the close of that day at 63? LOLPs. Check out the history of posts on that day and see what a fool you and your chums were at me shorting at 76 minutes after the Pfizer news broke out.

[mg1982] 03/11/2021 11:34

Tong - are you stupid or deliberately trying to mislead?

If someone held from 9 Nov 2020 to now they would have made approx 24% - not bad for a year's return.

[wan] 03/11/2021 10:40

To continue the theme previously highlighted regarding large diagnostic players reporting significant growth in their core businesses.

PerkinElmer reported their Q3 Results yesterday, further demonstrating the strength and continuation of demand led growth with their Non-COVID-19-related revenues in the business growing more than 50 percent year over year, and they raised their full year guidance.

[mg1982] 03/11/2021 10:15

Mr Tong - didn't I say it will be higher by YE? Have some patience

[tongosti] 03/11/2021 09:39

Morning mg - lost your enthusiasm this quickly sweetheart?

[tongosti] 02/11/2021 16:52

Not sure I lost anything (when the opposite is the case) on the stocks you mention, but the truth is hardly your interest Joe is it. Finally getting some colour on your cheeks sweetheart? Been a very long way innit. Lol.

[mg1982] 02/11/2021 16:22

Now is when you should be buying Tong.

You aint got a clue about charting - just humble yourself for once!

You lost out on SDI and EKF - don't make the same mistake thrice

[tongosti] 02/11/2021 10:00

Wan - since ekf is not following your incessant bullish posts for a very long time now, do you think there is a chance you can start educating us on other topics instead, say climate change?

[wan] 29/10/2021 07:43

How one company worked to help protect its employees and communities.....impressive!

"we know how to build at scale" watch the videos in the article below regarding labs and testing -

$15B in COVID-19-related costs to prioritize employee health and safety
Written by Amazon Staff
28th October 2021

Building testing labs to keep our teams safe

When the pandemic hit, we quickly changed many parts of how we work to help keep employees safe. We undertook one of the most comprehensive overhauls of our processes in Amazon’s 25-year history, including how our facilities were cleaned and how employees were trained. We also implemented social distancing measures, temperature checks, and other technologies. And we listened to our employees and public health experts and continued to adjust and update our processes regularly when we saw opportunities to do more.

For example, early in the pandemic, access to regular and reliable COVID-19 testing was scarce around the world. We didn’t wait for others to provide solutions. Instead, we assembled a team of professionals with a variety of skills—research scientists, program managers, procurement specialists, software engineers—and moved them from their day jobs to focus on creating a scalable COVID-19 testing program for their colleagues.

The initiative included building two diagnostic labs in a matter of months—one in the U.S. and another in the UK. Soon after launching, the labs were processing thousands of tests per day while continuing to build for more capacity. By October 2020, the U.S. lab in Kentucky was testing more than 700 employees an hour, making access to COVID-19 testing available to nearly all front-line employees.

By January 2021, our Kentucky lab reached a new milestone after processing 1 million tests for our employees. To date, we have processed many millions more across our labs. At the height of the pandemic, the labs were processing more than 30,000 tests a day. We also worked with public health entities to help the international fight against new strains of the virus.

Hear more from the team that built our in-house COVID-19 testing program and what drove their work.

Full article -

How we ramped up onsite COVID-19 testing for Amazon employees

Exclusive videos take you behind the scenes to meet the teams that established and scaled Amazon’s testing program.

"We built a strong cross-functional team—research scientists, engineers, procurement specialists, operators, financial analysts," she said. "Everybody left their own day job, and this became the focus."

Speaking in the early weeks of the team's work, Jeff Wilke, CEO Worldwide Consumer, said, "If we can build lab capacity and testing capacity that adds to the capacity that's available in the world, then we have made the world a safer place. I can't imagine anything more rewarding in this time of crisis."

Helping keep employees and customers safe

Cem Sibay, the Amazon Vice President who leads the testing project, said, "We all feel like we're going to help save lives here. We approach any delay as the most important thing that we need to solve for."

In addition to the original lab, there are now labs in Hebron, Kentucky and Manchester in the United Kingdom. Amazon is already conducting thousands of tests a day, and is on pace to conduct 50,000 tests a day across 650 sites by next month.

Full article -

That's a lot of testing scheduled for November and beyond!

[tongosti] 28/10/2021 17:56

Great to hear pal - do you think this is going to help any time soon EKF? Or just stretch out expectations by another 5 years and the hypothesis is still intact? Ta.

[wan] 27/10/2021 15:42

As expected, Thermo Fisher beat analysts Q3 expectations and lifts its annual forecast -

Thermo Fisher Scientific Reports Third Quarter 2021 Results
NEWS PROVIDED BY

Thermo Fisher Scientific
Oct 27, 2021, 06:00 ET

"Our incredibly strong performance in the third quarter demonstrates our proven growth strategy powered by our PPI Business System," said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. "We continue to deliver exceptional performance in revenue, earnings and free cash flow. And we are launching innovative new products and expanding our capabilities and capacity to enhance our customer value proposition."

Casper added, "Our team executed at a very high level during the first nine months of the year, and we are on track to deliver another outstanding year and set the company up for an even brighter future."

Third Quarter 2021

Revenue for the quarter grew 9% to $9.33 billion in 2021, versus $8.52 billion in 2020. Organic revenue growth was 7%; acquisitions increased revenue by 1% and currency translation increased revenue by 1%. Organic revenue growth from the base business was 10%. COVID-19 response revenue was $2.05 billion.

2021 Guidance Update

Thermo Fisher is raising its 2021 revenue and earnings guidance. The company is raising its revenue guidance by $1.2 billion to $37.1 billion; this would result in 15% revenue growth over 2020. The company is raising its adjusted EPS guidance by $1.30 to $23.37, which would represent 20% growth year over year.

Full release -

Thermo Fisher distribute a number of EKF products, including Primestore MTM and ATM and the recently launched Clia-waived handheld STAT-Site™ WB Meter, plus there is the production of a private label product in the works for Fisher too.

[wan] 27/10/2021 10:02

Relevant post from the Trellus Health thread -

When my own research (prior to Trellus listing) revealed how many large (and small) Pharma's were actively working on addressing different aspects of IBD (with some nearing FDA approval), combined with how Trellus plan to enter strategic industry partnerships with pharmaceutical companies to leverage its proprietary, anonymised longitudinal database to develop new products and inform clinical trials for existing and prospective drug treatments etc, it added to my rationale to significantly increase my investment in Trellus over and above my EKF in specie shares(via application and early market purchases).

I also find it reassuring that EKF, via ADL Health, could quickly provide any crucial/complimentary biomarker testing in the US for Trellus Health via their CLIA approved laboratory. Indeed, EKF highlighted the potential in their Growth Strategy for any CLIA lab purchase for diagnostic tests to link to Trellus, Renalytix and Verici.


Now part of the EKF Diagnostics Group

[tongosti] 25/10/2021 09:22

Thanks for sharing - journalists do what they do for a living for a reason pal don't they? According to the long term doctrine, if the first 10 years produce nothing, stretch one's horizon to 20 years or so and all will be fine right? Lol.

[travestor] 24/10/2021 05:13

a nice tip albeit not huge on detail, but it all helps:

[tongosti] 23/10/2021 13:09

Thanks pal - good logic doesn't go far enough - c19 has been discounted in its "entirety". Why? That's the way markets work. If c19 is not doing the trick for 12 months, this catalyst is totally done business wise. This company better have other irons on the fire (of the kind mr market can get a surprise from not what you think they are) otherwise you will all be calling c mills a genius for selling the top.

[wan] 23/10/2021 09:37

In my opinion, the key here is not to discount too much regarding COVID-19 testing (it will be with us for a long time, including potential curved balls in terms of variants), but importantly to look 'beyond' COVID-19 testing itself (but to include sample collection beyond COVID-19), as it is now widely accepted that Covid-19 has had an irreversible impact on healthcare as a whole, with some analysts predicting a major evolutionary shift, especially in terms of home diagnostics (and POCT).

EKF is transitioning on a number of fronts, of which home diagnostics is just one, with the planned expansion of their contract manufacturing to a broader range of diagnostic kits for other diagnostic companies, not to mention an expanded range of diagnostics across a broader suite of healthcare applications and settings.

[wan] 23/10/2021 09:25

The backdrop I previously highlighted, of large diagnostic players reporting strong results, continues with the likes of Danaher following suit. Importantly there is a continuing and underlying theme of a combined strong rebound and growth in their core businesses i.e. 'beyond' COVID-19 testing, with Danaher reporting that clinical diagnostic activity and patient volume have largely returned to pre-pandemic levels, and forecasting further core revenue growth.

I am expecting similar from Thermo Fisher Scientific next week.

EKF last reported improving trading in the core business. They also reported that overall, revenues from their hematology portfolio have been flat. Within this they have seen 12% growth of our DiaSpect Tm product, primarily driven by their OEM agreements with Fresenius and McKesson, a growth theme which I am expecting to continue, but which could receive a significant boost from the opportunity to start selling DiaSpect Tm into blood banks in the US.

EKF also referred to "hematology screening programmes have continued to be affected by the COVID-19 pandemic, although we have seen signs of programmes beginning to come online again in the latter part of the year, and in particular our major customer in Peru has started to significantly increase their orders as the territory opens up and much needed screening programmes are coming back online".

In this regard I note Peru's health minister recent comments from news yesterday -

"We're maintaining a high level of control," health minister Hernando Cevallos said recently.

"It is probable that the first and second waves have generated immunity in part of the population, as has vaccination."

And that the fall in infections has allowed the government to relax some healthcare measures and reactivate parts of the economy.

The government hopes to vaccinate 70 percent of its population over 12 by the end of the year.

More than 14.2 million people have so far received both vaccination doses, accounting for 51 percent of those aged over 12.

[tongosti] 22/10/2021 14:36

you're relying a lot on c19 test related kit pal. Any idea why the stock has stalled completely in the midst of this global pandemic? Ta

[tongosti] 22/10/2021 10:02

Wan - you da man

[wan] 22/10/2021 07:45

Readers will recall that as part of the 2021 – 2024 Growth Strategy EKF is investing into the Point of Care (POC) business to maximise distribution network and diversify existing product portfolio, so I am confident that this will also include additional POC products.

EKF is not only improving their current POC offering, they are readying for expansion -

EKF Link: A flexible connectivity solution for POC

Key Features
Connect multiple POC analyzers securely
Patient data, QC, Operator Management
Remote configuration of POC analyzers
Install on a PC, server or Cloud*

*The cloud solution will be introduced with a later release of EKF Link

One solution for multiple situations

EKF Link has been designed by IT Solution engineers working alongside hospital POC Managers to provide users with a single, comprehensive yet flexible platform.

EKF Link’s simple set-up, intuitive interface and user-friendly graphics enable effective utility in GP offices, pharmacies, laboratories, hospitals and blood banks. There are no barriers to where and how EKF Link can be implemented.

EKF Link can be installed on a PC (Windows or Apple), a server or can be operated via the Cloud* allowing access to authorized users anywhere at any time.

EKF Point of Care analyzers can be connected to EKF Link, the software has been designed to allow the addition of more analyzers as and when they are required.

Available now
EKF Link is now available to connect any of the following products* to a LIMS or HIS/EMR:

Hemo Control
Hemo Control Manager
DiaSpect Tm
Quo-Lab A1c
Quo-Test A1c

[wan] 22/10/2021 07:19

21st October 2021

EKF Diagnostics to showcase at Medica 2021 STAT-Site® WB β-ketone and glucose handheld analyzer live & in person

EKF Diagnostics will be exhibiting live & in person at Medica (Hall 3 Stand B71) for the first time in mainland Europe in two years. EKF’s presence at this show will give visitors the opportunity to catch up with its industry specialists face-to-face and see the recently launched STAT-Site® WB β-ketone and glucose handheld analyzer on its first public viewing in Europe since its global launch earlier this year.

In Medica’s Hall 3, EKF will provide expert point of care diagnostics knowledge and advice. It will also demonstrate the globally successful PrimeStore MTM novel viral transport media alongside the COVID-SeroKlir SARS-CoV-2 IgG antibody IVD kit, as well as showcase further new product innovations relating to the future control of COVID-19.

One of the world’s largest medical trade fairs, Medica will return to Düsseldorf on 15-18th November 2021 to highlight the best new and upcoming technologies in various sectors relating to clinical healthcare. To ensure the safety of visitors, there will be a plethora of COVID-19 safety measures in place, including proof of vaccination/recovery/negative test, ventilation, and sanitization points.

As the first live exhibition attended by EKF Diagnostics in mainland Europe in two years, it will be a perfect opportunity to display the newly released STAT-Site® WB. The dual-compound analyzer allows for easy and quick (5-10 seconds respectively) glucose and β-ketone measurement from whole blood samples. This delivers clear and rapid analysis for diabetic patients displaying ketosis symptoms, thus enabling their rapid treatment.

Other EKF diabetes care products to be exhibited will be the Biosen C-Line Glucose & Lactate analyzer. The device, which allows for the precise and efficient measurement of glucose and lactate in the blood, can measure the analytes individually or together depending on the model. Also on show will be EKF’s highly regarded Quo-Lab and Quo-Test HbA1c analyzers for the point-of-care measurement of glycated hemoglobin to support immediate monitoring and management of diabetes patients.

Members of the EKF’s growing Contract Manufacturing team will also be on-hand in Düsseldorf to offer tailored advice and discuss how EKF can help with kitting projects or bespoke fermentation requirements. From raw material sourcing to final packaging EKF can provide the full wing to wing contract manufacturing service.


The 'dual' analyte STAT-Site® WB is a differentiator and is likely to be very well received.